If Gilead's Hepatitis C Treatment Grosses $10B+ Per Year, Arrowhead's Hepatitis B Treatment Is Attractive.
- GILD's Hepatitis C treatment Sovaldi grossed $5.75B in 1H 2014. FY2014 targets range from $9B to $14B. It's a BLOCKBUSTER.
- ARWR has a hepatitis B treatment - ARC-520 - that is in Phase IIa development. It looks very promising so far. Further news is expected soon.
- Hepatitis B is roughly twice as prevalent as Hepatitis C, and there are no known "cures" yet. ARC-520 could be at least a "functional cure".
- If your interest has been peaked, there are many more details in the article below.